Details for Patent: 11,925,709
Which drugs does patent 11,925,709 protect, and when does it expire?
Patent 11,925,709 protects UBRELVY and is included in one NDA.
This patent has forty-two patent family members in thirteen countries.
Summary for Patent: 11,925,709
| Title: | Tablet formulation for CGRP active compounds |
| Abstract: | The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): wherein “Ra” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released. |
| Inventor(s): | Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, JR., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu |
| Assignee: | Merck Sharp and Dohme LLC |
| Application Number: | US17/110,398 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,925,709 |
|
Patent Claim Types: see list of patent claims | Compound; Dosage form; |
Drugs Protected by US Patent 11,925,709
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-002 | Dec 23, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,925,709
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015214502 | ⤷ Start Trial | |||
| Australia | 2019226239 | ⤷ Start Trial | |||
| Australia | 2021245229 | ⤷ Start Trial | |||
| Australia | 2021409718 | ⤷ Start Trial | |||
| Australia | 2023258317 | ⤷ Start Trial | |||
| Australia | 2025220825 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
